Maridebart cafraglutide vs Brenipatide
GLP-1 agonism paired with GIP receptor antagonism — the opposite GIP direction to tirzepatide. A once-monthly dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Maridebart cafraglutide MariTide | Brenipatide LY3537031 | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Investigational | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 agonist–GIP-antagonist peptide–antibody conjugate | GIP/GLP-1 dual agonist (acylated peptide) |
| Receptor | GLP-1 receptor (agonist) + GIP receptor (antagonist) | GIP + GLP-1 receptors |
| Molecular weight | ≈150,000 Da | ≈4,900 Da |
| Half-life | engineered for once-monthly dosing | |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Maridebart cafraglutide and Brenipatide?
- Maridebart cafraglutide is an engineered analog based on Glucagon-like peptide-1; Brenipatide is an engineered analog based on Glucagon-like peptide-1. Maridebart cafraglutide signals at GLP-1 receptor (agonist) + GIP receptor (antagonist); Brenipatide signals at GIP + GLP-1 receptors.
- How do the half-lives of MariTide and LY3537031 compare?
- The reported circulating half-life of Maridebart cafraglutide is ~21 days (monthly dosing); Brenipatide is engineered for once-monthly dosing. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Brenipatide vs Maridebart cafraglutide. Or open the interactive comparison tool to add more molecules.